e-learning
resources
ERJ
2006
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Long-term treprostinil in pulmonary arterial hypertension: is the glass half full or half empty?
Provencher S.
Source:
Eur Respir J 2006; 28: 1073-1075
Journal Issue:
December
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Provencher S.. Long-term treprostinil in pulmonary arterial hypertension: is the glass half full or half empty?. Eur Respir J 2006; 28: 1073-1075
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Diagnostic tools for Obstructive Sleep Apnoea in adults and children
Expert interview: Physiological classification of lung function impairment
Occupational exposures to respiratory diseases: A case-based discussion
Related content which might interest you:
Long-term continuous subcutaneous treprostinil therapy for pulmonary arterial hypertension (PAH)
Source: Eur Respir J 2003; 22: Suppl. 45, 461s
Year: 2003
Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil
Source: Eur Respir J 2006; 28: 1195-1203
Year: 2006
Long-term safety of a new formulation of epoprostenol in pulmonary arterial hypertension
Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment
Year: 2013
Intravenous iloprost for pulmonary arterial hypertension: still waiting for evidence
Source: Eur Respir J 2009; 34: 7-9
Year: 2009
Initial triple therapy in pulmonary arterial hypertension: coming of age and rejuvenated
Source: Eur Respir J, 57 (1) 2004258; 10.1183/13993003.04258-2020
Year: 2021
EPITOME-4, a phase 3b study evaluating a new formulation of epoprostenol sodium in pulmonary arterial hypertension following switch from Flolan®
Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment
Year: 2013
Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH)
Source: International Congress 2015 – Pulmonary hypertension: management
Year: 2015
Long-term treatment with oral sildenafil in addition to chronic prostacyclin therapy improves pulmonary hemodynamics and six minute walking test in patients with pulmonary arterial hypertension
Source: Eur Respir J 2002; 20: Suppl. 38, 598s
Year: 2002
Initial dual oral combination therapy for pulmonary arterial hypertension (PAH) in daily practice
Source: International Congress 2015 – Pulmonary hypertension: management
Year: 2015
Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2)
Source: Eur Respir J 2015; 45: 1303-1313
Year: 2015
Comparison of subcutaneous (sc) treprostinil use for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) in 2 Belgian centers
Source: Annual Congress 2010 - Pulmonary venous thromboembolic disease
Year: 2010
Safety and tolerability of rapid dose-titration of subcutaneous (SC) treprostinil in pulmonary arterial hypertension (PAH)
Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights
Year: 2015
Experience with subcutaneous treprostinil in children with pulmonary arterial hypertension
Source: International Congress 2017 – NICU/ PICU: evaluating short- and long-term ventilatory management
Year: 2017
Initial combination therapy with epoprostenol and bosentan in severe pulmonary arterial hypertension
Source: Annual Congress 2009 - Pulmonary arterial hypertension
Year: 2009
Hemodynamic effects of sildenafil in pulmonary arterial hypertension (PAH) patients
Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension
Year: 2005
Effect of riociguat on pulmonary arterial compliance (PAC) in patients with PAH in PATENT-1
Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights
Year: 2015
Parenteral treprostinil for significant pulmonary arterial hypertension associated with pulmonary fibrosis: A safety study
Source: Annual Congress 2011 - Treatment of pulmonary hypertension
Year: 2011
Experience with inhaled iloprost in paediatric pulmonary arterial hypertension
Source: Annual Congress 2011 - Treatment of human pulmonary hypertension
Year: 2011
Effect of intravenous epoprostenol on quality of life in pulmonary arterial hypertension
Source: Eur Respir J 2003; 22: Suppl. 45, 563s
Year: 2003
Inhaled iloprost for patients with pulmonary arterial hypertension and right heart failure
Source: Annual Congress 2010 - Pulmonary circulation I
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept